Eugene V. Kramolowsky

About

Dr. Eugene V. Kramolowsky is a leading urologic surgeon whose research has fundamentally advanced the treatment of benign prostatic hyperplasia (BPH), particularly for patients with large-volume prostates. His work centers on the development and validation of Aquablation therapy, a minimally invasive, robotically-guided waterjet ablation technique. Dr. Kramolowsky’s major contributions include landmark clinical trials demonstrating the long-term safety and efficacy of Aquablation for prostates sized 80-150 cc, an historically challenging patient population. His 2019 paper on 1-year results (63 citations) and the final 5-year WATER II trial results (49 citations) provide crucial evidence that Aquablation offers durable symptom relief with a favorable side-effect profile. Notably, his subgroup analysis from a blinded randomized trial (42 citations) showed that Aquablation preserves antegrade ejaculation significantly better than traditional TURP, a critical quality-of-life benefit. With over 178 combined citations for his most influential works, Dr. Kramolowsky’s research has reshaped clinical guidelines and offers a compelling, less invasive alternative for men suffering from severe BPH.

Research Focus

Key Achievements

Top Papers

1. 1
   Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results

   63 citations · 2019
2. 2
   Aquablation Therapy in Large Prostates (80-150 mL) for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Final WATER II 5-Year Clinical Trial Results

   49 citations · 2023
3. 3
   Symptom relief and anejaculation after aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial

   42 citations · 2018
4. 4
   Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results.

   24 citations · 2020

Key Collaborators

Contact & Links